TY  - CONF
AU  - Redondo-Rodriguez, R. 
AU  - Godoy-Navarrete, F.
AU  - Morales-Garrido, P.
AU  - Rojas-Gimenez, M.
AU  - Romero-Barco, C. M.
AU  - Mena-Vazquez, N.
PY  - 2022
DO  - 10.1136/annrheumdis-2022-eular.3166
SN  - 0003-4967
UR  - http://hdl.handle.net/10668/20095
T2  - Annals of the rheumatic diseases
AB  - Background: Interstitial Lung Disease (ILD) is the most common lung involvement in rheumatoid arthritis (RA) and leads to increased morbidity and mortality. Some retrospective observational studies suggest that abatacept (ABT) could be effective and...
LA  - en
PB  - Bmj publishing group
KW  - Abatacept
KW  - Retrospective studies
KW  - Prospective studies
KW  - Humans
KW  - Arthritis, rheumatoid
KW  - Lung diseases, interstitial
KW  - Morbidity
KW  - Lung
TI  - EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS.
TY  - conference output
VL  - 81
ER  -